Primary Biliary Cholangitis Treatment
Dec 12, 2023
Merck and Moderna Initiate Study to Evaluate V940; FDA Approves Vertex and CRISPR Therapeutics’ CASGEVY for SCD; Novartis Updated on its Investigational Iptacopan Phase III Study; FDA Grants Priority Review for New Drug Application for Elafibranor; FDA Approves bluebird bio’s LYFGENIA for Patients SCD; FDA Fast Track Designation for DMD Gene Therapy
Merck and Moderna Initiate INTerpath-002, a Phase III Study Evaluating V940 in Combination with KEYTRUDA for Adjuvant Treatment of Patients with Certain Types of Resected NSCLC Merck (also known as MSD outside the United States and Canada) and Moderna, Inc. have commenced the INTerpath-002 trial—a crucial Phase ...
Read More...
Feb 13, 2023
PPAR and NOX Agonist: Savior of Underserved Primary Biliary Cholangitis Patients
Primary biliary cholangitis (PBC), earlier known as primary biliary cirrhosis, is an autoimmune disorder that leads to the gradual destruction of intrahepatic bile ducts resulting in periportal inflammation cholestasis. Prolonged hepatic cholestasis subsequently leads to cirrhosis and portal hypertension. As per...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
